Ursodiol / UDCA (ursodeoxycholic acid)
What studies of Ursodiol / UDCA (ursodeoxycholic acid) found
At a glance, by condition
Long COVID: D Little or no difference
Based on the strongest evidence, the placebo trial (very low certainty), for overall symptoms.
1 outcome rated · see each below
Preventing long COVID: D Little or no difference
Based on the strongest evidence, compared with another group, not randomised (very low certainty): 3 findings, all D.
3 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: For long COVID, studies found little or no difference with Ursodiol / UDCA (ursodeoxycholic acid). For preventing long COVID, studies found little or no difference with Ursodiol / UDCA (ursodeoxycholic acid). If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- CMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- Ursodiol / UDCA (ursodeoxycholic acid) · Long COVID is hereUrsodiol / UDCA (ursodeoxycholic acid) · Preventing long COVID is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Daily life and health overall
Overall symptoms1 study · 132 people took Ursodiol / UDCA (ursodeoxycholic acid) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 396 people found no clear difference; a small benefit can't be ruled out.
The placebo trial396 randomised · 14 days · 900 mg once daily, 14 days
No clear difference in overall symptoms.
The evidence is very uncertain about the effect of Ursodiol / UDCA (ursodeoxycholic acid) on overall symptoms in long COVID. Little or no difference · very low certainty D
- Some concerns about bias (RoB 2)
- One trial of 396 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 396 randomised
- Dose
- 900 mg once daily, 14 days
- Outcome
- Difference in probability of recovery postacute sequelae of SARS-CoV-2 infection (PASC) index
- Effect
- no clear difference
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Preventing long COVID
Breathlessness1 study · 23,560 people took Ursodiol / UDCA (ursodeoxycholic acid) Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.
Compared with another group, not randomised469,108 in the study · 90-day period preceding cohort entry · at least one UDCA prescription within the 90-day period preceding cohort entry
No clear difference in breathlessness.
The evidence is very uncertain about the effect of Ursodiol / UDCA (ursodeoxycholic acid) on breathlessness later, when given during acute COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- The change wasn't shown to be more than chance
See the 1 study
-
Ursodeoxycholic acid and long COVID in steatotic liver disease: a nationwide cohort study. (2026)
- People in the study
- 469,108 in the study
- Dose
- at least one UDCA prescription within the 90-day period preceding cohort entry
- Outcome
- interstitial lung disease
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- Moderate. adjusted for: Age, sex, insurance type, dominant COVID-19 variant, comorbidities, concomitant medications, Charlson Comorbidity Index, COVID-19 vaccination history, lifestyle factors, SLD subtype
Age, sex, insurance type, and dominant COVID-19 variant were assessed at cohort entry.
- Selection of participants
- Moderate. comparison group: Patients without a documented UDCA prescription during the 90-day window were classified as non-users and served as the reference group.
Patients without a documented UDCA prescription during this 90-day window were classified as non-users and served as the reference group.
- Classification of interventions
- Moderate. from records after the fact
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: extent of missing data was minimal
Given the use of NHIS- and registry-based administrative data, the extent of missing data was minimal.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- Moderate. a pre-specified secondary outcome
Depression1 study · 23,560 people took Ursodiol / UDCA (ursodeoxycholic acid) Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.
Compared with another group, not randomised469,108 in the study · 90-day period preceding cohort entry · at least one UDCA prescription within the 90-day period preceding cohort entry
No clear difference in depression.
The evidence is very uncertain about the effect of Ursodiol / UDCA (ursodeoxycholic acid) on depression later, when given during acute COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- The change wasn't shown to be more than chance
See the 1 study
-
Ursodeoxycholic acid and long COVID in steatotic liver disease: a nationwide cohort study. (2026)
- People in the study
- 469,108 in the study
- Dose
- at least one UDCA prescription within the 90-day period preceding cohort entry
- Outcome
- depression
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- Moderate. adjusted for: Age, sex, insurance type, dominant COVID-19 variant, comorbidities, concomitant medications, Charlson Comorbidity Index, COVID-19 vaccination history, lifestyle factors, SLD subtype
Age, sex, insurance type, and dominant COVID-19 variant were assessed at cohort entry.
- Selection of participants
- Moderate. comparison group: Patients without a documented UDCA prescription during the 90-day window were classified as non-users and served as the reference group.
Patients without a documented UDCA prescription during this 90-day window were classified as non-users and served as the reference group.
- Classification of interventions
- Moderate. from records after the fact
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: extent of missing data was minimal
Given the use of NHIS- and registry-based administrative data, the extent of missing data was minimal.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- Moderate. a pre-specified secondary outcome
Sleep1 study · 23,560 people took Ursodiol / UDCA (ursodeoxycholic acid) Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.
Compared with another group, not randomised469,108 in the study · 90-day period preceding cohort entry · at least one UDCA prescription within the 90-day period preceding cohort entry
No clear difference in sleep.
The evidence is very uncertain about the effect of Ursodiol / UDCA (ursodeoxycholic acid) on sleep later, when given during acute COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- The change wasn't shown to be more than chance
See the 1 study
-
Ursodeoxycholic acid and long COVID in steatotic liver disease: a nationwide cohort study. (2026)
- People in the study
- 469,108 in the study
- Dose
- at least one UDCA prescription within the 90-day period preceding cohort entry
- Outcome
- insomnia
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- Moderate. adjusted for: Age, sex, insurance type, dominant COVID-19 variant, comorbidities, concomitant medications, Charlson Comorbidity Index, COVID-19 vaccination history, lifestyle factors, SLD subtype
Age, sex, insurance type, and dominant COVID-19 variant were assessed at cohort entry.
- Selection of participants
- Moderate. comparison group: Patients without a documented UDCA prescription during the 90-day window were classified as non-users and served as the reference group.
Patients without a documented UDCA prescription during this 90-day window were classified as non-users and served as the reference group.
- Classification of interventions
- Moderate. from records after the fact
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: extent of missing data was minimal
Given the use of NHIS- and registry-based administrative data, the extent of missing data was minimal.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- Moderate. a pre-specified secondary outcome
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
900 mg at the start
- 2Top dose
Most often 900 mg (1 of 1 studies)
Doses across 1 study
900 to 900 mg.
Each study’s dose, as printed
- 900 mg once daily, 14 days Neither Metformin nor Ursodeoxycholic Acid Effectively Treats Postacute Sequelae of COVID-19 : A Randomized Clinical Trial. (2026)
All papers
- Neither Metformin nor Ursodeoxycholic Acid Effectively Treats Postacute Sequelae of COVID-19 : A Randomized Clinical Trial.2026 · placebo trial · 396 randomised
- Ursodeoxycholic acid and long COVID in steatotic liver disease: a nationwide cohort study.2026 · compared with another group · 469,108 in the study
Summary
This nationwide retrospective cohort study used the Korean COVID-19 registry linked to National Health Insurance Service claims data (2019–2022) to examine whether pre-infection ursodeoxycholic acid (UDCA) use was associated with long COVID outcomes in patients with steatotic liver disease (SLD) and COVID-19. The base cohort included 469,108 patients with SLD infected with COVID-19; 23,560 (5.0%) were UDCA users and 445,548 (95.0%) were non-users. UDCA exposure was defined as at least one prescription within the 90-day period preceding cohort entry. The study assessed 20 incident long COVID conditions across eight organ systems from 84 days after infection, with median follow-up ranging from 134.3 to 141.6 days. After propensity score fine stratification, UDCA use was not associated with reduced risk for most long COVID outcomes. A protective association was observed for atrial fibrillation (HR 0.51, 95% CI 0.30–0.88), whereas increased risks were found for type 2 diabetes mellitus (HR 1.24, 95% CI 1.09–1.42) and epilepsy (HR 1.69, 95% CI 1.09–2.61). No harms of UDCA were reported for this study. The authors state that the observational design precludes causal inference and residual confounding cannot be completely excluded.